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Summary. Background: Coagulation factor XII is a serine
protease that is important for kinin generation and blood
coagulation, cleaving the substrates plasma kallikrein and
FXI. Objective: To investigate FXII zymogen activation
and substrate recognition by determining the crystal
structure of the FXII protease domain. Methods and
results: A series of recombinant FXII protease constructs
were characterized by measurement of cleavage of chro-
mogenic peptide and plasma kallikrein protein substrates.
This revealed that the FXII protease construct spanning
the light chain has unexpectedly weak proteolytic activity
compared to b-FXIIa, which has an additional nine
amino acid remnant of the heavy chain present. Consis-
tent with these data, the crystal structure of the light
chain protease reveals a zymogen conformation for active
site residues Gly193 and Ser195, where the oxyanion hole
is absent. The Asp194 side chain salt bridge to Arg73
constitutes an atypical conformation of the 70-loop. In
one crystal form, the S1 pocket loops are partially flexi-
ble, which is typical of a zymogen. In a second crystal
form of the deglycosylated light chain, the S1 pocket
loops are ordered, and a short a-helix in the 180-loop of
the structure results in an enlarged and distorted S1
pocket with a buried conformation of Asp189, which is
critical for P1 Arg substrate recognition. The FXII struc-
tures define patches of negative charge surrounding the
active site cleft that may be critical for interactions with
inhibitors and substrates. Conclusions: These data provide
the first structural basis for understanding FXII substrate
recognition and zymogen activation.
Keywords: active site; catalytic domain; factor XII; plasma
prokallikrein; tertiary protein structure; zymogens.
Introduction
FXII is a central component of the contact system, which
also includes the serine proteinase prekallikrein (PK) and
the non-enzymatic cofactor high molecular weight kinino-
gen [1]. FXII circulates in the blood as an 80-kDa single-
chain polypeptide zymogen with no detectable enzymatic
activity. The contact system can be activated by diverse
negatively charged polymers, including kaolin [1], nucleic
acids [2], and collagen [3]. It has also been recently dem-
onstrated that neutrophil extracellular traps, which form
networks of fibers primarily composed of DNA, can acti-
vate the contact system in a process linked to innate
immunity, the generation of antimicrobial peptides, and
complement activation [4].
The FXII Arg353–Val354 peptide bond is cleaved by
kallikrein, generating a-FXIIa, which has a heavy chain
of 50 kDa, connected to a light chain of 28 kDa by the
Cys340–Cys467 disulfide bridge. Once a small amount of
a-FXIIa is generated, this cleaves PK to generate kallik-
rein, which then mediates efficient cleavage of further
FXII in a feedback loop that amplifies production of
a-FXIIa and kallikrein. Subsequent cleavage of a-FXIIa
results in loss of the heavy chain and generation of the
isolated protease domain termed b-FXIIa, which contains
only a nine amino acid peptide heavy chain remnant
disulfide bonded to the protease domain [1].
Human genome-wide studies have reported associations
of single-nucleotide polymorphisms in FXII with throm-
bosis and a shortening of the activated partial thrombo-
plastin time [5]. FXII knockout mice are protected
against thrombosis and ischemic stroke in models of the
disease [6]. It has been proposed that targeting of FXII
could result in medicines with a safer anticoagulation pro-
file than the currently available anticoagulants, such as
warfarin [7]. A recently described antibody, 3F7, which
binds specifically to the FXII protease domain forms the
basis of a new anticoagulation therapy [8].
FXII has evolved from duplication of the hepatocyte
growth factor activator (HGFA) gene ancestor. Both
have a similar domain organization, which consists of an
N-terminal fibronectin type II domain (FnII) followed by
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an epidermal growth factor-like (EGF)1 domain, fibro-
nectin type I (FnI), an EGF2 domain, a Kringle domain,
and a C-terminal serine protease domain with an addi-
tional Pro-rich (PR) region unique to FXII (Fig. 1A). A
crystal structure has been described for the FXII fibronec-
tin type I domain and EGF2 domain, but no structure
exists for the protease [9]. Here, we describe the first crys-
tal structures of the FXII protease domain, which reveals
a zymogen-like conformation.
Materials and methods
Cloning, expression, and purification
A gene fragment encoding human FXII light chain resi-
dues Val354–Ser596 (mature protein sequence numbering)
was cloned into the pMT puro vector for expression with
the DES system (Invitrogen, Carlsbad, CA, USA) [10].
The Cys467Ser point mutation was introduced by overlap
PCR mutagenesis to remove an unpaired Cys that could
potentially cause aggregation. At the N-terminus, the sig-
nal sequence corresponds to a Drosophila homolog of the
immunoglobulin-binding chaperone protein secretion sig-
nal, and at the C-terminus a polyhistidine tag sequence
HHTGTRHHHHHH was added. Use of the BglII
restriction site resulted in two additional residues, Arg
and Ser, at the N-terminus of the FXII sequence, and this
sample was termed FXIIc. This restriction site was
deleted with overlap PCR mutagenesis to generate the
native catalytic domain FXIIac (a = active; c = catalytic
domain). Drosophila S2 cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine seum at 28 °C, and transfection was performed
with calcium phosphate. Cells were grown for an addi-
tional 48 h before selection with puromycin to establish
stable cell lines. Serum-free Express Five insect culture
medium (Invitrogen), containing secreted proteins, was
collected, and 30–85% (NH4)2SO4 fractionation resulted
in a protein pellet; further purification was performed
with Ni–sepharose column affinity chromatography and
gel filtration chromatography. N-terminal sequencing of
the purified samples confirmed the removal of the signal
peptide and that the correct sequence was present at the
N-terminus. Deglycosylation with PNGase F (NEB,
Hitchin, UK) was carried out for 24 h at 30 °C in 50 mM
sodium phosphate (pH 7.4).
Crystallization and structure determination
Purified samples of FXIIac and FXIIc were dialyzed into
20 mM Tris-HCl (pH 7.4) and 100 mM NaCl, and concen-
trated to 17 mg mL1. Crystallization was performed at
19 °C and 10 °C with sparse matrix screens (Qiagen,
Hilden, Germany; Molecular Dimensions, Newmarket,
UK) in sitting drop plates. Crystals were observed for
glycosylated FXIIac in conditions of 0.1 M HEPES
(pH 7.5), 1.6 M (NH4)2SO4, and 2% (w/v) poly(ethylene
glycol) 1000 in the presence of PPACK at 10 °C. Degly-
cosylated FXIIc grew from solutions containing 1.2 M
(NH4)2SO4, 0.05 M trisodium citrate, and 3% isopropa-
nol. Single crystals were transferred to the reservoir solu-
tion containing 25% glycerol, and flash cooled in liquid
nitrogen. Diffraction data were collected at DIAMOND
beamline I04, at 2.4 A for FXIIac and 2.1 A for FXIIc.
Data were processed and reduced with XDS [11] and the
CCP4 suite in space groups P3221 (FXIIac) and P41212
(FXIIc). The structures were determined by molecular
replacement (PHASER) with coordinates from the HGFA
protease domain (Protein Data Bank [PDB]: 1YC0). Both
models were built with COOT [12] and refined with REFMAC
(Table 1).
Assays of FXII activity
Amidolytic activity was measured with the chromogenic
substrate H-D-Pro-Phe-Arg-p-nitroaniline, termed S2302
(Chromogenix, Epsom, UK) [13]. FXIIc and FXIIac
(final protein concentration: 1.5 lM), b-FXIIa (0.0333 lM)
and a-FXIIa (0.0253 lM) were assayed at 37 °C in a final
volume of 100 lL of 0.01 M phosphate buffer (0.0027 M
potassium chloride and 0.137 M sodium chloride, pH 7.4).
Initial rates were determined with 2 mM S2302 substrate
by measuring the release of p-nitroaniline at 405 nm.
In the assay measuring PK conversion to kallikrein
b-FXIIa (1 nM), FXIIc (5 nM) and FXIIac (5 nM) were
incubated with PK (50 nM) in reaction buffer containing
200 lM S2302 (Chromogenix) at 37 °C protein concentra-
tion. Changes in OD405 nm reflecting conversion of PK to
a-kallikrein were monitored with a microplate reader.
For kinetic experiments, the fluorogenic substrate Pro-
Phe-Arg-7-AMC (P9273; Sigma, Gillingham, UK) was
used to measure enzymatic activity in a 30-lL final volume
of phosphate-buffered saline (pH 7.3) (BR0014G; Oxoid,
Basingstoke, UK) supplemented with 0.03% Tween-20.
The reaction was started by addition of enzyme to the sub-
strate, after which release of the fluorescent group was
monitored every 5 min for 5 h by excitation at 380 nm
and emission at 460 nm. The enzyme activity rates at con-
stant enzyme–substrate concentration were determined
from the time course and used to derive the kinetic param-
eters. Data were fitted in GRAPHPAD PRISM, with the non-
linear regression Michaelis–Menten algorithm (Table 2).
Mass spectrometry
Nano-electrospray ionization mass spectra were collected
on a Waters SYNAPT instrument (Elstree, UK) with a
quadruple time-of-flight mass analyzer calibrated with
horse heart myoglobin. Samples were prepared by desalt-
ing FXIIc with a C4 ZipTip into 80 : 20 MeCN/H2O and
0.1% trifluoroacetic acid. Subsequent mass spectra were
acquired over a 500–5000 m z1 range in positive ion
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Fig. 1. FXII domain boundaries and constructs. (A) The domain structure of FXII is shown at the top (FnII, Fibronectin type II domain; EGF,
epidermal growth factor-like domain; FnI, fibronectin type I domain; PR, Pro-rich region), and illustrated below are the constructs FXIIc and
FXIIac used in this study, with the unpaired Cys467 mutated to Ser highlighted. The heavy chain (HC) remnant (HCR) resulting from autoprote-
olysis of FXII is boxed for b-FXIIa. The shaded region at the N-terminus of FXIIc represents the N-terminal cap of two residues, Arg and Ser.
(B) Enzymatic activities of the recombinant proteases FXIIc and FXIIac (1.5 lM) are illustrated, as assessed with the S2302 peptide substrate
cleavage assay, as compared with commercial a-FXIIa (0.0253 lM) and b-FXIIa (0.0333 lM). The scale on the y-axis is logarithmic. (C) The rate
of enzymatic activity of FXII proteases measured in the prekallikrein (PK) cleavage experiments shown in (D) is presented with a scale on the
y-axis that is logarithmic. (D) Native substrate PK (50 nM) was incubated in reaction buffer containing S2302 peptide substrate, in the presence
of b-FXIIa (■) (1 nM), FXIIac (▲) (5 nM), and FXIIc (●) (5 nM). Cleavage of S2302 was monitored by following changes in OD405 nm. PK alone
(♢) and FXII samples at the concentration used do not cleave S2302 at any appreciable rate in the absence of PK (○, □, M). (E) Specific proteo-
lytic cleavage of substrate PK is shown for FXIIc and b-FXIIa. Anti-human PK polyclonal antibody western blots of SDS-PAGE are shown for
a time course of PK proteolysis in the presence of b-FXIIa protease (top gel), a 109 concentration of the FXIIc active site mutant Ser195Ala
(middle gel), and FXIIc (bottom gel). Lanes 1–5 represent 0–120 min. The arrows to the right of each blot indicate the zymogen PK and the HC
and two light chains (LCs) of cleaved PK. The positions of molecular mass standards (kDa) are shown on the left of the figure.
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mode. Minimal smoothing and noise reduction of spectra
were applied to the raw data.
Results
Recombinant FXII light chain catalytic activity
The recombinant proteins investigated were FXIIac,
which has the native N-terminus, and a zymogen-like
protease FXIIc, in which the N-terminus is blocked by
the presence of two additional amino acids, Arg and Ser.
SDS-PAGE of the purified proteins is shown in Fig. S1,
and N-terminal sequencing was performed, confirming the
expected residues at the N-terminus and proper removal
of the secretory signal sequence (data not shown). The
Asn74 N-linked glycan in the recombinant FXIIc was
characterized by mass spectrometry, which revealed
masses corresponding to two species that were either
2GlcNac + 4Man or 2GlcNac + Fuc (Fig. S1). Commer-
cially available b-FXIIa represents an autoproteolytic
end-product resulting from incubation of plasma-purified
FXII zymogen with dextran sulfate (Enzyme Research
Laboratories, Swansea, UK). b-FXIIa contains a nine
amino acid remnant peptide sequence NGPLSCGQR
spanning residues 335–343 termed the heavy chain rem-
nant.
To characterize the catalytic activity of the two recom-
binant FXII proteins, we measured the hydrolysis of
chromogenic peptide substrate S2302 in comparison with
a-FXIIa and b-FXIIa by using published methodology
[14]. The FXIIac protease catalyzed cleavage of S2302,
whereas the zymogen-like protease FXIIc had ~ 10-fold
lower measurable activity (Fig. 1B). Unexpectedly, a com-
parison of FXIIc with commercial plasma-purified
a-FXIIa and b-FXIIa revealed a ~ 1000-fold greater rate
of substrate cleavage for the latter (Fig. 1B). This experi-
ment was repeated with a second fluorescent peptide sub-
strate, Pro-Phe-Arg-7-AMC (Sigma) [14]; this confirmed
these results, and measured values of kcat/Km are shown
in Table 2. To verify this observation, we utilized a third
assay, which involves cleavage of the native substrate PK
by the FXII protease samples and measurement of enzy-
matic activity with the resulting activated PK. The results
from this indirect assay revealed a reduced rate of ~ 10-
fold less cleavage for FXIIac than for b-FXIIa, and ~ 10-
fold less for FXIIc than for FXIIac (Fig. 1C). Control
experiments in this assay with PK or FXII alone did not
result in measurable substrate cleavage (Fig. 1D). To
examine the cleavage of PK by our FXII samples, we
used a time course monitored with SDS-PAGE, and, as
expected, addition of FXIIc and b-FXIIa to PK resulted
in specific cleavage, generating the characteristic fragmen-
tation resulting in bands for the PK heavy (single band)
and light (double band) chains (Fig. 1E).
Table 1 Data collection and refinement statistics
FXIIc FXIIac
Data collection
Space group P41212 P3221
Cell dimensions
a, b, c (A) 124.1, 124.1, 38.2 137.1, 137.1, 37.0
a, b, c (°) 90, 90, 90 90, 90, 120
Wavelength (A) 0.9763 0.97949
Resolution (A) 2.1 2.4
Rmerge * 0.085 (0.378) 0.069 (0.816)
I/rI 23.0 (1.71) 11.0 (2.3)
Completeness (%) 95.2 (84.3) 98.2 (98.6)
Multiplicity 12.9 5.6
CC 1/2† 1.00 (0.98) 1.00 (0.76)
Unique reflections 16 114 15 737
Refinement‡
Rwork 0.222 (0.279) 0.218 (0.397)
Rfree 0.262 (0.278) 0.295 (0.417)
Overall B-factor (A2) 29.2 73.6
Stereochemical r.m.s.d.
Bond lengths (A) 0.013 0.016
Bond angles (°) 1.86 1.96
Ramachandran plot
Most favored (%) 93.3 85.3
Allowed (%) 6.7 14.7
Outliers (%) 0 0
r.m.s.d., root mean square deviation. *Values in parentheses corre-
spond to the highest-resolution shell. *Rmerge = Σh Σi|Ii(h)  <I(h)
>/|ΣhΣiIi(h), where I is the observed intensity and <I> is the average
intensity of multiple observations from symmetry-related reflections
calculated with XDS. †Correlation coefficient value calculated with
XDS to determine the resolution cutoff. ‡All values were calculated
with REFMAC. Rwork = Σh||Fo|h  |Fc|h|/Σh|Fo|h, where Fo and Fc are
the observed and calculated structure factors, respectively. Rfree was
computed as for Rwork, but only for (5%) randomly selected reflec-
tions, which were omitted from refinement.
Table 2 Enzyme kinetic parameters for factor XII
Sample kcat(s
1) Km (lM) kcat/Km (L mol
1 s1)
a-FXIIa 0.67  0.01 222  3 2991
b-FXIIa 0.76  0.01 260  8 2904
FXIIac 0.67 9 103  0.01 9 103 195  4 3
FXIIc 2.90 9 105  0.09 9 105 283  13 0.1
FXIIc S195A < 0.01 9 103 ND ND
ND, not determined. Enzymatic activity was measured as described. Values are given as reported, with the standard error of the regression
analysis calculated with GRAPHPAD PRISM (non-linear regression with the Michaelis–Menten equation).
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The notable difference between the S2302/7-AMC pep-
tide substrate and PK cleavage experiments probably
reflects the different requirements for the enzyme to
cleave the tripeptide sequence of S2302 and to cleave the
large 80-kDa substrate of PK, which may undergo addi-
tional interactions with the FXII protease. Overall, these
data reveal that the native FXIIac light chain has 10-fold
reduced catalytic activity in a PK cleavage assay as com-
pared with b-FXIIa, and a 1000-fold reduced activity
cleaving tripeptide substrates.
The FXIIac crystal structure
Using the recombinant FXIIac protease in crystallization
experiments, we followed a similar approach as the FXI
protease (FXIac) [15] of cocrystallization with the inhibi-
tors PCK, PPACK, and corn trypsin inhibitor. FXIIac
crystallized both in the presence and in the absence of
PPACK at 10 °C, and the FXIIac crystal structure was
determined by molecular replacement with the structure
of the homologous HGFA protease and refined to an
R-factor of 0.219 (data collection and refinement statistics
are summarized in Table 1). The topology is shown in
Fig. 2A, with the characteristic double b-barrel fold with
the catalytic triad of His57, Asp102 and Ser195 shown.
The nomenclature of chymotrypsin residue numbering is
used throughout with FXII mature residue numbering,
and the corresponding FXII immature residue numbers
are listed in Table S1 for key residues. There are six disul-
fide bridges in the FXIIc structure, three of which are
well conserved among other chymotrypsin-like proteases
(Cys42–Cys58, Cys168–Cys182, and Cys191–Cys220), two
(Cys50–Cys111 and Cys136–Cys201) of which occur in
HGFA [16] and tissue-type plasminogen activator (t-PA)
[17], and one of which (Cys77–Cys80) is unique to FXII
(Fig. S2). Two GlcNAc residues could be observed in the
electron density, and were modeled covalently linked to
Asn74, where they undergo loose packing interactions
with the N-terminal b-barrel.
A key feature that identifies the FXIIac structure as a
zymogen is the absence of an oxyanion hole (Gly193 and
Ser195) and a buried zymogen-like conformation of the
Asp194 side chain, whereby it forms hydrogen bonds with
the main chain nitrogen of Trp141. A second feature is
that residues 182–183 from the 180-loop and resi-
dues 217–221 from the 220-loop of the S1 pocket are not
visible in the electron density. We have previously
observed in the FXI zymogen crystal structure, where
there are no crystal packing contacts in the area of the
active site, that the 180-loop and 220-loop are also
not present in the electron density, suggesting S1 loop
flexibility [18]. The FXIIac zymogen conformation was
unexpected, but is in agreement with the enzyme kinetic
data described above, which showed that FXIIac has
reduced catalytic activity as compared with b-FXIIa. The
N-terminus is not observed in the FXIIac electron
density, and Val16–Leu23 are presumed to be flexible,
and do not efficiently insert into the core of the protease
domain in this context (see discussion).
FXIIc crystal structure
FXIIc is a protein-engineered zymogen-like construct with
two additional residues present at the N-terminus, result-
ing from the cloning strategy, that effectively block the
native N-terminal residue Val354. We term this the zymo-
gen-like construct, as it is similar to the result of protein
engineering of the N-terminus of FXa to induce zymoge-
nicity [19]. FXIIc crystallized more readily than FXIIac
under a range of conditions for both glycosylated and de-
glycosylated samples at 19 °C. Data were collected to 2.1-
A resolution for the deglycosylated FXIIc sample
(Table 1), and Fig. 2D shows the electron density in the
region of the active site residue Ser195.
An additional feature observed in FXIIc but not in
FXIIac is that the S1 pocket structure is clearly defined
and all residues from the 180-loop and 220-loop are
observed, with coiling of residues 189–194 into a single
turn of an a-helix (colored pink in Fig. 2C). In FXIIc,
Arg73 extends its side chain guanidinium group from the
70-loop of the N-terminal b-barrel to form a direct salt
bridge with the buried Asp194 side chain (Fig. 2D). The
Arg73 side chain from the 70-loop is stabilized by a num-
ber of interactions with the 140-loop, resulting in encircle-
ment of the Arg73 guanidinium group and the formation
of hydrogen bonds via the side chain of Gln151 (Fig. 2E).
The conformation of the S34 pocket is maintained in
FXIIac and FXIIc, but the region of the H1 pocket is
altered, with a 90° rotation of the Trp35 side chain and a
shift in the main chain, resulting in a repositioning of this
residue such that it now forms a lid on top of the H1
pocket and becomes partially buried.
A catalytically incompetent conformation of the FXIIac and
FXIIc active site
We performed comparisons with the FXIIc structure and
the activated Ser protease domain of HGFA, which is the
closest homolog to FXII in amino acid identity [20].
Superposition of FXIIc with the HGFA catalytic domain
resulted in 222 equivalent residues with an overall root
mean square deviation (r.m.s.d.) of 1.8 A (47% amino
acid identity; DALI [21]). The C-a traces of the superposed
structures are illustrated in Fig. 3A. Residues from the
catalytic triad and the N-terminal b-barrel superimpose
well, whereas large differences are observed in the
C-terminal b-barrel and loop-140, loop-180, and loop-
220. The largest difference observed is a 25-A change for
the tip of the 140-loop; a smaller 14-A change is observed
for the 220-loop. In HGFA, the 140-loop forms a
hairpin-like structure folded up against the side of the
C-terminal b-barrel, interacting with the 180-loop close to
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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Fig. 2. FXII protease structures. (A) Cartoon diagram of the FXIIac topology colored from the N-terminus to the C-terminus, with the N-ter-
minal b-barrel in blue/green and the C-terminal b-barrel in yellow/orange. Loops containing residue ranges derived from the chymotrypsin
sequence numbering are labeled 70s, 140s, 180s, and 220s. Disulfide bonds are shown in yellow. Regions not visible in the electron density are
shown as dotted lines. (B) Cartoon diagram of the FXIIc structure. (C) FXIIac and FXIIc crystal structures superposed. The two structures
are represented as cartoon traces with the 180-loop colored pink and the 220-loop colored green. (D) Electron density map (2Fo – Fc coeffi-
cients) for the final refined coordinates of FXIIc at 2.1-A resolution shown in the area of the active site residue Ser195 contoured at 1.5 root
mean square deviation. Isopropanol molecules bound in the H1 pocket are shown in green as sticks, and water molecules as red crosses. (E)
Interactions between loops from the two FXIIc b-barrels are shown, illustrating how Arg73 connects to residues from both the 180-loop and
140-loop. The 80-loop, 140-loop and 220-loop are colored orange, green, and cyan, respectively, with S1 helix residues in red. Electrostatic and
hydrogen-bonding interactions are shown as purple dotted lines. The positively charged residues Arg72, Arg73 and His75 from the 70-loop are
shown as sticks in orange.
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the entrance of the S1 pocket [22]. This folded-up 140-
loop conformation is commonly observed in activated
proteases, and contrasts with FXIIc, in which the 140-
loop extends away from the body of the C-terminal b-
barrel.
The FXIIc S1 pocket structure superposed with the
HGFA protease structure, which has a Kunitz domain
(KD)1 inhibitor bound [23], is shown in Fig. 3B. In the
HGFA–KD1 complex, the side chain groups of Asp189
and Gln192 engage the substrate P1 Arg side chain and
P2 main chain, respectively, and the P1 Arg main chain
carbonyl contacts the oxyanion hole main chain nitrogens
[16,23]. There are three areas of major conformational
difference between the HGFA and FXIIc structures that
confirm that FXIIc is a catalytically incompetent zymo-
gen structure: (i) the peptide bond of Asp194 is flipped by
180°, resulting in the absence of the oxyanion hole; (ii)
Asp189 is folded back in the S1 pocket, and undergoes a
water-mediated interaction with the side chain of Tyr228
(Fig. 3B); and (iii) the largest change affects the side
chain of Gln192, which is displaced by 12 A, forming a
hydrogen bond with the side chain of Thr188 in FXIIc.
Asn223 from the adjacent loop forms an a-helix-capping
hydrogen bond with the main chain nitrogen of Ala190.
All residues that contact the inhibitor in HGFA are in
different positions in FXIIc, by virtue of the concerted
coiling of residues 189–194 into the FXII S1 a-helix.
These three differences in the 180-loop and 140-loop fur-
ther characterize the FXIIc structure as having a zymogen
conformation.
FXIIc surface pockets and charge distribution
The FXII protease amino acid sequence is acidic, with a
calculated pI of 5.2. An electrostatic potential surface rep-
resentation of the area around the active site loops reveals
99 Loop
S1
220 Loop
S1
D194
R73
I16D189
180 Loop
140 Loop
FXII
(S1 helix)
Absent
oxyanion
hole
HGFA
160 Loop
A
B
Fig. 3. FXIIc structural comparisons with the activated protease hepatocyte growth factor activator (HGFA). (A) C-a traces are shown for
superposed protease domains FXIIc (red) and HGFA (green). (B) Close-up view of the superposition in the area of the S1 pocket shows key
side chains highlighted as sticks. The HGFA S1 pocket structure illustrates the conformation of an activated protease bound to inhibitor (Ku-
nitz domain, KD1) shown in orange (only two residues from KD1 are shown, and interactions are shown as dotted purple lines. Main chain
nitrogen atoms from the HGFA oxyanion hole are shown as blue spheres.
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clusters of negatively charged residues organized into two
patches, which encircle the substrate-binding pockets
labeled R1 (Asp60A, Glu62, and Asp63) and R2
(Glu151B, Glu151E, and Glu151F) in Fig. 4A. The two
patches surround the active site, and a 90° rotation of the
surface in Fig. 4A shows that the negative charge extends
down the exterior face of the N-terminal b-barrel. Interest-
ingly, a sequence alignment with related proteases reveals
that the negatively charged patch R1 also occurs in uroki-
nase plasminogen activator (u-Pa), whereas R2 only occurs
in FXII (Fig. S3). This overall charge character contrasts
with thrombin, which has positively charged anion-binding
exosites (overall calculated pI of 8.8 for the thrombin pro-
tease sequence). The 3F7 antibody, which binds specifically
to the FXII protease domain and forms the basis of a new
anticoagulation therapy [8], has been mapped as binding
to Asp60 from patch R1 and Ile101 from the area of the
S34 pocket, and thus probably functions by sterically
blocking substrate binding to FXI and PK (Fig. 4A).
The H1 pocket is a distinctive feature that is located in
the center of the N-terminal b-barrel, with the side chains
of Leu33, Leu64, Leu59, Leu106 and Trp35 contributing
to the hydrophobic character, and is positioned directly
in front of the S1 pocket in the C-terminal b-barrel
(Figs 2D and 4A). The shape of the S1, S2, S3 and S4
pockets is of special interest, as coagulation protease sub-
strates and inhibitors commonly interact here [24]. The
area of the S34 pocket is formed by the 220-loop, 170-
loop, and 99-loop, with Trp215 being a constant feature
of this pocket, occurring in all of the coagulation prote-
ases [16] and FXII. The FXIIc S34 pocket is shown in
Fig. 4B, with Trp215 and Tyr99 highlighted. Superposi-
tion of FXIIc with the crystal structures of the homolo-
gous u-PA (42% identity, r.m.s.d. 2.2 A, 225 equivalent
residues, PDB 3MHW) and t-PA (42% identity, r.m.s.d.
2.3 A, 225 equivalent residues, PDB 1RTF) reveals that
u-PA also has an insertion in the 99-loop, whereas t-PA
has the closest similarity, with the same 99-loop length as
FXII. t-PA also has the Tyr99 present in FXII, and the
loop structures are closely superimposable. Examination
of other coagulation factors reveals that the more dis-
tantly related FXa also has this arrangement, and Fig. 4B
shows that Met180 is present as a constant feature in all
three of these proteases, contributing to the bottom of
the S34 pocket.
Discussion
In the current study, we report the first crystal structures
of the FXII protease domain light chain. Both FXIIac
and protein-engineered zymogen-like construct FXIIc
structures reveal the conformational hallmarks of a zymo-
gen, owing to the lack of an oxyanion hole, a disordered
(FXIIac) or helical (FXIIc) 180-loop, and an extended
140-loop. The disordered portions of the 180-loop and
220-loop in the FXIIac structure are consistent with
3F7 antibody site
S3
S1
H1
R1
R2
tPA
FXa
R2
R1
90°
W215
S175
M180
S34
Y99
FXIIc
Q60
H57
A B
Fig. 4. FXIIc surface pockets and charge. (A) Charge surface representation of the FXIIc crystal structure (negative = red and positive = blue).
Ridges of negative charge are labeled R1 and R2. S1, S34 and H1 pockets are labeled. Two views related by a 90° rotation are shown. (B)
Zoom-in view of the S34 pocket structure for FXIIc (top), with side chains shown as sticks (green) and equivalent residues shown for tissue-
type plasminogen activator (t-PA) (middle) and FXa (bottom) colored orange.
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nuclear magnetic resonance studies on thrombin, which
has a similar S1 pocket architecture to FXII, showing
that these loops are disordered in solution in the absence
of substrate [25].
The zymogen conformation of FXIIac is unexpected, as
protease constructs for u-Pa, FXIa and trypsin lacking a
heavy chain remnant have been crystallized in the active
conformation [15,26,27]. To determine a structural basis
for this difference, we generated a homology model of
b-FXIIa by using the HGFA structure (program SWISSMOD-
EL [28]). Figure 5A shows the HGFA crystal structure with
the activation loop (blue) and remnant (orange) high-
lighted, and the model of b-FXIIa is shown in Fig. 5B.
Eight amino acids from the HGFA remnant are present in
the crystal structure (PDB: 1YC0), which only partially
overlaps with the remnant present in b-FXIIa, which is
proteolyzed further to Arg343. One feature observed in
HGFA and the majority of the trypsin-like class of prote-
ase structures is a b-hairpin in the C-terminal region of the
activation loop involving residues 23–26. In HGFA, direct
interactions are observed between the remnant and this
b-hairpin, whereby the Arg397 side chain has a hydrogen-
bonding interaction with the carbonyl group of Ser26. In
the homology model of b-FXIIa, Arg343 is equivalent to
Arg397, and is modeled undergoing a similar interaction
with the base of the activation loop.
A structural basis for the low catalytic activity and the
zymogen-like conformation of FXIIac could be that a
FXlac structure
HGFA structure
FXlIac structure
I16,L17
I16,L17
S20
T20
V16,V17
140 Loop
140 Loop
L23
L23
V16
R24
L23
V23
R24
D116
P24
Remnant Remnant
R397 C340 R343
β -Hairpin
β -Hairpin
β -Hairpin
β -FXIIa modelA B
C D
Fig. 5. Cartoon diagrams showing stabilizing interactions in the region of the heavy chain remnant (orange) and the activation loop (blue) are
compared for different proteases with salt bridges or hydrogen bonds illustrated as a dotted purple line. (A) Hepatocyte growth factor activator
(HGFA) (Protein Data Bank [PDB]: 1YC0), (B) b-FXIIa, homology model, (C) FXIa (PDB: 1XX9), which has no remnant, and (D) the
FXIIac structure reported here. The FXIIac activation loop does not have a formed b-hairpin, and residues after Leu23 are not present in the
electron density (dotted blue line).
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direct interaction between the remnant and the amino
acids of the activation loop is required to form the b-hair-
pin, and thus for Val16 to be positioned correctly to
insert into the protease core and form the S1 pocket.
Clearly, not all proteases have this requirement, as some
are produced without the remnant, such as FXIa shown
in Fig. 5C. Here, it is notable that, unlike in FXIIa, the
FXIa activation loop forms two salt bridges from Glu26
and Arg24 to residues in the protease domain [15].
Evidence of stabilizing interactions in the region of the b-
hairpin is also observed in the trypsin structure, where no
remnant is present, and the b-hairpin conformation is
fixed by a disulfide bond from Cys22 to Cys157. These
types of stabilizing interaction are absent in the model of
b-FXIIa.
A novel structural feature that we observe in FXIIac
and FXIIc is that the 70-loop has an unusual conforma-
tion, whereby Arg73 extends to form a salt bridge with
the side chain of Asp194. The engagement of the negative
Asp194 carboxyl group is a key switch between the acti-
vated and inactive forms of chymotrypsin-like proteases.
In the zymogen crystal structures of chymotrypsinogen,
FXI, trypsin, and plasminogen [29], an Asp194–His40
side chain interaction is observed. His40 is not present in
FXII, whereas the side chain of Arg73 occupies a similar
position to His40 (Fig. 6). Further structural studies on
the full-length FXII zymogen coupled with mutagenesis
experiments will be required to verify whether Arg73
plays a role in stabilizing the FXII zymogen and whether
the remnant is required to stabilize the activated form in
FXIIa.
The negatively charged amino acid clusters surrounding
the S1 pocket define surface patches that distinguish FXII
from other coagulation proteases, and could potentially
interact with substrates and inhibitors. This could com-
plement the overall net positive charge of the substrate,
FXI, implying that charge complementary is important
for efficient FXII substrate recognition. These features
contrast with those of thrombin, which has well-charac-
terized positively charged exosites on the surface of the
protease domain. Both thrombin and FXIIa can activate
FXI, but thrombin cleavage has a greater dependence on
the addition of polyanions than FXIIa [30].
Targeting coagulation factor serine protease active sites
with inhibitors is the subject of intensive research, and
studies with antibodies that bind FXII have suggested
that this may provide an effective form of anticoagulation
therapy [8,31]. Overall, the data presented here provide
novel and important contributions to our understanding
of the structure of the FXII protease zymogen conforma-
tion, and provide an initial basis for understanding both
substrate and inhibitor binding and zymogen activation.
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